B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

(2021) Zhuoming Liu et al.   Cell Host & Microbe

The Variant Gambit: COVID’s Next Move

(2021) Jessica A. Plante et al.   Cell Host & Microbe

SARS-CoV-2 spike D614G change enhances replication and transmission

(2021) Bin Zhou et al.   NATURE

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

(2021) Naveenchandra Suryadevara et al.   CELL

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

(2021) Matthew McCallum et al.   CELL

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

(2021) Markus Hoffmann et al.   CELL

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant

(2021) Xianding Deng et al.   CELL

Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries

(2021) Rui Wang et al.   GENOMICS

SARS-CoV-2 vaccines: a triumph of science and collaboration

(2021) Jonathan L. Golob et al.   JCI Insight

Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021

(2021) Finlay Campbell et al.   Eurosurveillance

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

(2021) Emma C Wall et al.   LANCET

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

(2021) Jianying Liu et al.   NATURE

SARS-CoV-2 variants of concern are emerging in India

(2021) Jasdeep Singh et al.   NATURE MEDICINE

Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer

(2020) Sufang Tian et al.   Journal of Thoracic Oncology

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

(2020) Zhe Xu et al.   Lancet Respiratory Medicine

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

A human neutralizing antibody targets the receptor binding site of SARS-CoV-2

(2020) Rui Shi et al.   NATURE

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

(2020) Christopher O. Barnes et al.   CELL

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

(2020) Fabian Schmidt et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

(2020) Lihong Liu et al.   NATURE

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

(2020) Xiangyang Chi et al.   SCIENCE

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

(2020) Johanna Hansen et al.   SCIENCE

Distinct conformational states of SARS-CoV-2 spike protein

(2020) Yongfei Cai et al.   SCIENCE

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

(2020) Shengli Xia et al.   LANCET INFECTIOUS DISEASES

Spike mutation D614G alters SARS-CoV-2 fitness

(2020) Jessica A. Plante et al.   NATURE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of Four SARS-CoV-2 Neutralization Assays

(2020) Lydia Riepler et al.   Vaccines

A Vesicular Stomatitis Virus Replicon-Based Bioassay for the Rapid and Sensitive Determination of Multi-Species Type I Interferon

(2011) Marianne Berger Rentsch et al.   PLoS One